Anti-CCP and Diagnosing Rheumatoid Arthritis

Dr Daman Langguth

writer

Dr Daman Langguth

Head of the Immunology Department at Sullivan Nicolaides Pathology; Chair of Sullivan Nicolaides Pathology Partners.

Dr Daman Langguth

Historical and Pathological Background

Research in rheumatoid arthritis (RA) over the past 10 years has gained significant ground in both pathophysiological and clinical understanding.

It is now known that early aggressive therapy within the first three months of the development of joint symptoms decreases the chance of developing severe disease, both clinically and radiologically.

PASSWORD RESET

Forgot your password or password not working? Please enter your email address. You will receive an email with the link to set a new password.

References

  1. ACR Position statement on anti-CCP antibodies http://www.rheumatology.org/publications hotline/1003anticcp.asp.
  2. Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B; BARFOT Study Group. Prediction of radiologic outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 2004; 63(9):1090-5. DOI: 10.1136/ard.2003.014233
  3. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 Shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005 Nov; 52(11): 3433-8. DOI: 10.1002/art.21385
  4. Lee DM, Schur PH. Clinical Utility of the anti-CCP assay in patients with rheumatic disease. Ann Rheum Dis. 2003 Sep; 62(9): 870-4. DOI: 10.1136/ard.62.9.870
  5. van Gaalen FA1, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. Arthritis Rheum. 2004 Mar; 50(3): 709-15. DOI: 10.1002/art.20044
  6. Zendman AJW, van Venrooij WJ, Prujin GJM. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology. 2006 Jan; 45(1): 20-5. DOI: 10.1093/rheumatology/kei111
Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof William Kemp

A/Prof William Kemp

Cardiovascular Risk and Fatty Liver Disease

Dr Adam Nelson

Dr Adam Nelson

CV Medications – Practical Strategies to Improve Compliance

Prof Merlin Thomas

Prof Merlin Thomas

SGLT2s and Renal Protection

Dr Ryan De Cruz

Dr Ryan De Cruz

Importance of Early & Effective Treatment of Mild to Moderate Acne

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Dr Daman Langguth

writer

Dr Daman Langguth

Head of the Immunology Department at Sullivan Nicolaides Pathology; Chair of Sullivan Nicolaides Pathology Partners.

Test your knowledge

Recent articles

Latest GP poll

The government's bulk billing incentives start on 1 November. How accurate do you think the government's messaging to the public has been?

Very misleading

0%

Moderately misleading

0%

Slightly misleading

0%

Not at all misleading

0%

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Upcoming Healthed Webcast

Panel discussion on GLP1s for chronic kidney disease in type 2 diabetes

TONIGHT Tuesday 28th October, 7pm - 9pm AEDT

Panellists

Prof Genie Pedagogos, Prof Richard MacIsaac & A/Prof Ralph Audehm

Paediatric Allergist and Immunologist; Royal Children's Hospital

We invite you to our next free webcast, where an expert panel will discuss GLP1s for CKD in T2D. Up to 4 hours CPD. RACGP & ACRRM accredited.